MX366223B - Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. - Google Patents
Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.Info
- Publication number
- MX366223B MX366223B MX2015006548A MX2015006548A MX366223B MX 366223 B MX366223 B MX 366223B MX 2015006548 A MX2015006548 A MX 2015006548A MX 2015006548 A MX2015006548 A MX 2015006548A MX 366223 B MX366223 B MX 366223B
- Authority
- MX
- Mexico
- Prior art keywords
- repeat domains
- binding proteins
- against her2
- domains against
- repeat
- Prior art date
Links
- 108091008324 binding proteins Proteins 0.000 title abstract 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195156.0A EP2738180A1 (en) | 2012-11-30 | 2012-11-30 | Binding proteins comprising at least two binding domains against HER2. |
| PCT/EP2013/075290 WO2014083208A1 (en) | 2012-11-30 | 2013-12-02 | Binding proteins comprising at least two repeat domains against her2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015006548A MX2015006548A (es) | 2015-10-15 |
| MX366223B true MX366223B (es) | 2019-07-03 |
Family
ID=47257683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006548A MX366223B (es) | 2012-11-30 | 2013-12-02 | Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10370414B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2738180A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6410724B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102290592B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104918959A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013351096C9 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2892747C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1211297A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX366223B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2664464C9 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014083208A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| EP2643348B1 (en) * | 2010-11-26 | 2025-02-12 | Molecular Partners AG | Improved capping modules for designed ankyrin repeat proteins |
| AU2013331763B2 (en) * | 2012-10-15 | 2018-02-15 | Universitat Zurich | Bispecific HER2 ligands for cancer therapy |
| JP6486908B2 (ja) | 2013-05-31 | 2019-03-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 肝細胞増殖因子に結合する設計アンキリン反復タンパク質 |
| CA2931356A1 (en) | 2013-11-27 | 2015-06-04 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
| JP6872482B2 (ja) | 2014-11-27 | 2021-05-19 | ザイムワークス，インコーポレイテッド | Ｈｅｒ２を標的とする二重特異性抗原結合性構築物の使用方法 |
| US10858405B2 (en) | 2015-02-06 | 2020-12-08 | Navigo Proteins Gmbh | EGFR binding proteins |
| IL276944B (en) | 2015-04-02 | 2022-07-01 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
| PL3322721T4 (pl) | 2015-07-16 | 2022-06-06 | Navigo Proteins Gmbh | Nowe białka wiążące immunoglobulinę i ich zastosowanie w oczyszczaniu na bazie powinowactwa |
| US10584152B2 (en) | 2015-07-20 | 2020-03-10 | Navigo Proteins Gmbh | Binding proteins based on di-ubiquitin muteins and methods for generation |
| CN107849147B (zh) * | 2015-07-20 | 2021-09-17 | 纳维格蛋白质有限公司 | 基于二泛素突变蛋白的Her2结合蛋白 |
| CA3022751A1 (en) | 2016-05-04 | 2017-11-09 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
| RU2627215C1 (ru) * | 2016-05-24 | 2017-08-03 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" | Рекомбинантный таргетный токсин, специфичный к клеткам, экспрессирующим рецептор her2 |
| CN109476712B (zh) | 2016-08-11 | 2022-08-02 | 纳维格蛋白质有限公司 | 新型对碱稳定的免疫球蛋白结合蛋白 |
| NZ751689A (en) * | 2016-09-22 | 2021-07-30 | Molecular Partners Ag | Recombinant binding proteins and their use |
| MX2019006374A (es) | 2016-12-02 | 2019-09-11 | Univ Southern California | Receptores inmunes sinteticos y metodos de usos de ellos. |
| EP3706804B1 (en) | 2017-11-07 | 2022-02-23 | Navigo Proteins GmbH | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
| CA3139164A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| AU2020286715A1 (en) * | 2019-06-04 | 2021-12-23 | Molecular Partners Ag | Recombinant 4-1 BB binding proteins and their use |
| WO2020245171A1 (en) * | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Designed ankyrin repeat domain with improved stability |
| WO2020245746A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Multispecific proteins |
| CA3147423A1 (en) | 2019-07-26 | 2021-02-04 | Abl Bio Inc. | Anti-her2/anti-4-1bb bispecific antibody and use thereof |
| CN114929730A (zh) | 2019-12-11 | 2022-08-19 | 分子合作伙伴股份公司 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
| JP2023525518A (ja) | 2020-05-06 | 2023-06-16 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規アンキリンリピート結合タンパク質とその用途 |
| WO2021229067A1 (en) | 2020-05-14 | 2021-11-18 | Molecular Partners Ag | Multispecific proteins |
| CN115996945A (zh) * | 2020-05-14 | 2023-04-21 | 分子合作伙伴股份公司 | 重组cd40结合蛋白及其用途 |
| US20240108746A1 (en) | 2020-12-16 | 2024-04-04 | Molecular Partners Ag | Novel slow-release prodrugs |
| JP2024509890A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | プロテアーゼ切断可能なプロドラッグ |
| CA3211248A1 (en) | 2021-03-09 | 2022-09-15 | Nina RESCHKE | Novel darpin based cd33 engagers |
| MX2023010543A (es) | 2021-03-09 | 2023-10-13 | Molecular Partners Ag | Ligadores multiespecificos de celulas t novedosos basados en darpin. |
| WO2022190018A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| AU2022413461A1 (en) | 2021-12-14 | 2024-06-06 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| US20240228545A9 (en) | 2022-08-01 | 2024-07-11 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| JP4086325B2 (ja) | 1997-04-23 | 2008-05-14 | プリュックテュン，アンドレアス | 標的分子と相互作用する（ポリ）ペプチドをコードする核酸分子の同定方法 |
| HK1039355B (en) | 1998-12-02 | 2007-09-21 | Bristol-Myers Squibb Company | Dna-protein fusions and uses thereof |
| AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| US8124085B2 (en) * | 2004-05-05 | 2012-02-28 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| KR20150140417A (ko) * | 2004-07-22 | 2015-12-15 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| WO2007006665A1 (en) | 2005-07-08 | 2007-01-18 | University Of Zürich | Phage display using cotranslational translocation of fusion polypeptides |
| AU2007223888A1 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Genetic packages and uses thereof |
| EA021222B8 (ru) | 2007-06-21 | 2015-11-30 | ИксЭль-ПРОТЕИН ГМБХ | Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro |
| WO2009040338A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zürich | Designed armadillo repeat proteins |
| US20110189203A1 (en) | 2007-11-27 | 2011-08-04 | Ablynx N.V. | Immunoglobulin constructs |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| MX359570B (es) | 2008-11-03 | 2018-10-01 | Molecular Partners Ag | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
| TW201120210A (en) * | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| EP2643348B1 (en) | 2010-11-26 | 2025-02-12 | Molecular Partners AG | Improved capping modules for designed ankyrin repeat proteins |
| JP2014519808A (ja) | 2011-04-29 | 2014-08-21 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ４／ｉｌ１３に結合する反復タンパク質及び使用 |
| WO2012162418A1 (en) * | 2011-05-23 | 2012-11-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for heterodimeric targeting ligands |
| AU2013283296A1 (en) | 2012-06-28 | 2015-02-05 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| AU2013331763B2 (en) | 2012-10-15 | 2018-02-15 | Universitat Zurich | Bispecific HER2 ligands for cancer therapy |
| JP6486908B2 (ja) | 2013-05-31 | 2019-03-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 肝細胞増殖因子に結合する設計アンキリン反復タンパク質 |
-
2012
- 2012-11-30 EP EP12195156.0A patent/EP2738180A1/en not_active Withdrawn
-
2013
- 2013-12-02 US US14/648,611 patent/US10370414B2/en active Active
- 2013-12-02 WO PCT/EP2013/075290 patent/WO2014083208A1/en not_active Ceased
- 2013-12-02 CN CN201380062520.9A patent/CN104918959A/zh active Pending
- 2013-12-02 MX MX2015006548A patent/MX366223B/es active IP Right Grant
- 2013-12-02 CA CA2892747A patent/CA2892747C/en active Active
- 2013-12-02 HK HK15110090.1A patent/HK1211297A1/xx unknown
- 2013-12-02 JP JP2015544498A patent/JP6410724B2/ja not_active Expired - Fee Related
- 2013-12-02 AU AU2013351096A patent/AU2013351096C9/en not_active Ceased
- 2013-12-02 EP EP13811818.7A patent/EP2925784B1/en active Active
- 2013-12-02 KR KR1020157017376A patent/KR102290592B1/ko not_active Expired - Fee Related
- 2013-12-02 RU RU2015120663A patent/RU2664464C9/ru active
-
2018
- 2018-11-01 AU AU2018256592A patent/AU2018256592A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014083208A1 (en) | 2014-06-05 |
| KR20150091138A (ko) | 2015-08-07 |
| JP6410724B2 (ja) | 2018-10-24 |
| AU2013351096B2 (en) | 2018-08-09 |
| JP2015537044A (ja) | 2015-12-24 |
| RU2664464C9 (ru) | 2018-12-19 |
| EP2925784B1 (en) | 2021-02-17 |
| AU2013351096A1 (en) | 2015-07-09 |
| WO2014083208A9 (en) | 2014-12-24 |
| RU2015120663A (ru) | 2017-01-10 |
| RU2664464C2 (ru) | 2018-08-17 |
| CA2892747A1 (en) | 2014-06-05 |
| US10370414B2 (en) | 2019-08-06 |
| EP2925784A1 (en) | 2015-10-07 |
| CN104918959A (zh) | 2015-09-16 |
| CA2892747C (en) | 2022-07-19 |
| AU2013351096C9 (en) | 2019-01-31 |
| BR112015012436A2 (pt) | 2017-09-12 |
| EP2738180A1 (en) | 2014-06-04 |
| MX2015006548A (es) | 2015-10-15 |
| KR102290592B1 (ko) | 2021-08-19 |
| HK1211297A1 (zh) | 2016-05-20 |
| AU2018256592A1 (en) | 2018-11-22 |
| AU2013351096C1 (en) | 2018-11-08 |
| WO2014083208A8 (en) | 2014-10-30 |
| US20150299265A1 (en) | 2015-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015006548A (es) | Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. | |
| CY1119567T1 (el) | Θεραπευτικα πεπτιδια | |
| CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
| IN2012DN00640A (cg-RX-API-DMAC7.html) | ||
| MX2014008102A (es) | Inmunoglobulinas de dominio variable dual contra receptores. | |
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| PH12012502115A1 (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| MY164906A (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| BR112014019579A2 (pt) | Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero | |
| NZ714128A (en) | 4-1bb binding molecules | |
| IN2015MN00139A (cg-RX-API-DMAC7.html) | ||
| MX2015011075A (es) | Peptidos terapeuticos. | |
| UA106900C2 (uk) | Агоністичний dr5-зв'язувальний поліпептид | |
| UA110049C2 (uk) | ЛІКУВАННЯ ОСТЕОАРТРИТУ ІМУНОГЛОБУЛІНОВИМ ЗВ'ЯЗУВАЛЬНИМ БІЛКОМ З ПОДВІЙНИМ ВАРІАБЕЛЬНИМ ДОМЕНОМ, ЩО ЗВ'ЯЗУЄ IL-1α І IL-1β | |
| EA201690314A1 (ru) | Анти-garp-белок и его применения | |
| MX342034B (es) | Proteinas monovalentes que se unen a antigenos. | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| MX2012013406A (es) | Variantes de union mejoradas anti-albumina serica. | |
| MX2011008752A (es) | Variantes de union a anti-albumina de suero mejoradas. | |
| PH12014501818A1 (en) | Pseudomonas aeruginosa pcrv binding single variable domain antibodies | |
| PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| MX2011008749A (es) | Variantes de union a anti-albumina de suero mejoradas. | |
| MX2015013803A (es) | Proteina de fusion de enlace al cartilago. | |
| PH12019500677A1 (en) | Cmet monoclonal binding agents, drug conjugates thereof and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |